Compare DraftKings Inc (DKNG) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Medpace Holdings Inc — how do they compare? DraftKings Inc trades at $19.32 (market cap $9.86B), while Medpace Holdings Inc trades at $614.07 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Medpace Holdings Inc for 14 Days on average.
| DKNG | MEDP | |
|---|---|---|
Market Cap | $9.86B | $16.82B |
Volume | 16,584,596 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $630.19 |
52-Week Low | $18.59 | $393.42 |
Typical Hold Time | 55 Days | 14 Days |
Enterprise Value | $10.80B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.43, down 1.46% on the day and near 52-week lows. The technical picture is bearish with weak moving averages, while fundamentals show strong revenue growth to $6.05B in 2025 but negative profitability metrics. Recent earnings misses and high valuation multiples create headwinds, though analyst sentiment remains overwhelmingly bullish with a $33.13 price target.
The stock faces near-term pressure from technical weakness and earnings volatility, but long-term prospects are supported by market share leadership and prediction platform expansion. Key risks include competitive threats, regulatory uncertainty, and the sustainability of current valuation levels amid profitability challenges.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
